Home › Free Stock Grades › VYGR
Voyager Therapeutics, Inc. (VYGR) Stock Grade
VYGR · Healthcare
C+
Market Cap
$230.7M
P/E Ratio
—
Revenue Growth (YoY)
-49.5%
Net Margin
-296.5%
Return on Equity
—
Dividend Yield
None
About Voyager Therapeutics, Inc.'s fundamentals
Voyager Therapeutics is a biotechnology company with a market capitalization of $230.7 million that is currently unprofitable, reporting a net loss in its latest annual statement and a net margin of -296.5%. The company experienced significant revenue contraction, with year-over-year revenue declining 49.5%, indicating substantially reduced sales activity. As a development-stage biotech firm, Voyager does not pay a dividend and lacks meaningful profitability metrics like price-to-earnings ratio and return on equity.